PAS om dagens konkurrent-nytt
NVS’ acquired IgA drug shows no eGFR effect as expected
Novartis this morning reported “successful” 36-weeks phase 3 results of Atrasentan, the drug it bought with the acquisition of Chinook Therapeutics for USD 3.5 bn in August. Novartis will try to submit to the FDA for accelerated approval while expecting the final readout of the phase 3 only in Q1 2026. [ We previously wrote (link) ], why we did not expect this drug to succeed, and todays’ readout confirms that again. Novartis reported 36-week proteinuria data (creatinine measured in urine, a biomarker used for assessing eGFR) but no eGFR data i.e. there is no effect in our view at week 36 as there was none for Sparsentan. In brief, Calliditas’ Nefecon (Tarpeyo/Kinpeygo) will remain the only safe and effective treatment, the company just has to sell more aggressively which will become much easier once full approval is granted (expected for 20 December 2023). We reiterate our Buy rating on CALTX with a target price of SEK 230
Short var passe stor i 21, no er vi straks i 24 og short er enorm! Skulle tro shorterene ga seg snart da det egentlig ser veldig bra ut her! De må da trekke short om kina markedet åpner opp for produktet deres ?